Integrated Pharmacokinetic/Pharmacodynamic Model of XV459, a Potent and Specific GPIIb/IIIa Inhibitor, in Healthy Male Volunteers

Author:

Fossler Michael J.,Ebling William F.,Ma Su,Kornhauser David,Mondick John,Barrett Jeffrey S.,Garner Dennis,Quon Check Y.,Pieniaszek Henry J.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference23 articles.

1. Disposition and exposure of the fibrinogen receptor antagonist XV459 on αIIBβ3 binding sites in the guinea pig;Barrett;Biopharm Drug Dispos,1999

2. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459;Mousa;Arterioscler Thromb Vasc Biol,1999

3. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3;Mousa;Pharmacol Exp Ther,1998

4. Daly R Ebling W Pieniaszek H Cain V Kopecky S Murphy J Roxifiban, a new oral IIb/IIIa glycoprotein receptor antagonist, in patients with coronary artery disease June 1011, 1999

5. Nonlinear pharmacokinetics of a novel platelet glycoprotein IIb/IIIa receptor antagonist, XV459, in beagle dogs;Kapil;Pharm Res,1996

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3